AI Article Synopsis
Article Abstract
Objectives: The objectives of this study were to determine the prevalence of frailty in the context of atrial fibrillation (AF); to identify the most commonly used frailty instruments in AF; and to describe the effect of frailty on non-vitamin K oral anticoagulant (NOAC) prescription for stroke prevention in adults with AF.
Methods: A systematic search of databases, including Medline, Embase, Web of Science, Cochrane Library, Scopus, and CINAHL, was conducted using search terms including "atrial fibrillation," "frailty," and "anticoagulation." A narrative synthesis was undertaken.
Results: A total of 92 articles were screened, and 12 articles were included. The mean age of the participants ( = 212,111) was 82 years (range = 77-85 years) with 56% of participants identified as frail and 44% identified non-frail. A total of five different frailty instruments were identified: the Frailty Phenotype (FP; = 5, 42%), the Clinical Frailty Scale (CFS; = 4, 33%), Cumulative Deficit Model of Frailty (CDM; = 1, 8%), Edmonton Frail Scale ( = 1, 8%) and the Resident Assessment Instrument - Minimum Data Set (RAI-MDS 2.0; = 1, 8%). Frailty was identified as an important barrier to anticoagulant therapy with 52% of the frail population anticoagulated vs 67% non-frail.
Conclusion: Frailty is an important consideration in anticoagulation decision making for stroke prevention in patients with AF. There is scope to improve frailty screening and treatment. Frailty status is an important risk marker and should be considered when evaluating stroke risk alongside congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke, transient ischemic attack, or thromboembolism, vascular disease, age 65-74 years, sex category (CHADS-VASc) and Hypertension, Abnormal renal/liver function, Stroke, Bleeding, Labile, Elderly, and Drugs (HAS-BLED) scores.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242262 | PMC |
| http://dx.doi.org/10.1002/agm2.12214 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Significance of frailty in mortality and complication after hepatectomy for patients with liver cancer: a systematic review and meta-analysis.
HPB (Oxford)
December 2024
Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of China Medical University, Shenyang, 110001, China.
Background: Frailty has been associated with increased mortality and complications among liver cancer patients. However, the frailty prevalence and outcomes in frail populations with primary liver cancer have not been systematically validated.
Methods: Embase, PubMed, Scopus, and Web of Science were searched for eligible studies that explored the prevalence and impact of frailty in liver cancers from inception until October 26, 2023.
Waldenström Macroglobulinemia-Induced Cardiac Amyloid Light Chain Amyloidosis.
Ochsner J
January 2024
Division of Cardiology, Baylor Scott & White Medical Center, Temple, TX.
Waldenström macroglobulinemia is a rare cancer of plasma cells characterized by the excessive production of immunoglobulin M (IgM). IgM-associated systemic amyloid light chain (AL) amyloidosis is a rare complication of Waldenström macroglobulinemia, characterized by the misfolding of lambda light chains that deposit in various organs, including the heart. We describe a case of progressive nonischemic cardiomyopathy secondary to Waldenström macroglobulinemia and IgM-associated AL amyloidosis that was refractory to medical therapy and highlight the challenges in diagnosis and management.
View Article and Find Full Text PDFEffects of 12-Week Moderate-Intensity Versus High-Intensity Water-Aerobic Training on Physical Fitness, Cardiovascular Health, and Well-Being in Adults and Older Adults: A Pragmatic Randomized Controlled Trial.
Health Sci Rep
December 2024
Department of Sport Sciences University of Beira Interior Covilhã Portugal.
Background And Aims: The current study aimed to compare the effects of 12 weeks of moderate versus high-intensity water aerobics on muscle strength, body composition, lipid profile, blood pressure, and quality of life in both adults and older adults.
Methods: Twenty-one women (65.19 ± 9.
Background: For the time being, tafamidis is the only approved treatment for wild-type transthyretin cardiac amyloidosis. However, benefits on all-cause death only emerge after ≈18 months. The current available staging systems are unable to specifically discriminate patients at high risk of death within 18 months from diagnosis, and the selection of patients who are expected to benefit from tafamidis is left to the clinical judgment of treating physicians, being often based primarily (and sometimes only) on age.
View Article and Find Full Text PDFCorrigendum to "Understanding frailty and its opposites from community-dwelling older people's perspectives: A phenomenological qualitative study" [International Journal of Nursing Studies Advances 7 (2024) 100238].
Int J Nurs Stud Adv
December 2024
FAITH research, Groningen, Leeuwarden, the Netherlands.
[This corrects the article DOI: 10.1016/j.ijnsa.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!